Comparison of Two Analgosedation Regimens in Transfemoral TAVI: Propofol-Dexmedetomidine vs. Propofol-Remifentanil
The Heart Surgery Forum · 02.04.2026 · 29 (4)
DOI: 10.31083/hsf47124 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Heart Surgery Forum, online erschienen am 02.04.2026. Verfasst von Erik Thies Merks und 5 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study aimed to compare the hemodynamic effects of two analgosedation regimens, Remifentanil/Propofol vs. Dexmedetomidine/Propofol, during transfemoral transcatheter aortic valve implantation (tf-TAVI).
Methods
In this monocentric, prospective, non-randomized observational study, 143 patients undergoing tf-TAVI between November 2021 and November 2023 were analyzed. Patients received either Remifentanil/Propofol or Dexmedetomidine/Propofol as part of their standard sedation regimen. A sensitivity analysis using propensity score matching was performed to support the primary analysis.
Results
The primary outcome was circulatory stability, assessed by the need for catecholamines to maintain a mean arterial pressure (MAP) of 65 mmHg. Catecholamine use was significantly higher in the Dexmedetomidine group (78% vs. 55%; p = 0.012). No significant differences were observed in major post-procedural complications (Remifentanil: 19.05% vs. Dexmedetomidine: 13.56%; p = 0.389) or postoperative delirium scores. However, intraoperative agitation, defined as observed procedure disruption, was significantly less frequent in the Remifentanil group (33% vs. 69%; p = 0.01). Propensity score matching confirmed the robustness of these findings.
Conclusion
In conclusion, both sedation strategies were associated with comparable overall clinical outcomes in patients undergoing tf-TAVI. However, our findings suggest that a tailored sedation approach may be warranted: Remifentanil–Propofol may be preferable in patients with fragile hemodynamics, whereas dexmedetomidine–propofol may represent a safer option in patients at risk for respiratory compromise. These observations support an individualized, patient-centered sedation strategy rather than a one-size-fits-all approach.
Zitieren
APA
Merks, E. T., Heide, M. V. D., Meyer-Jark, T., Wille, C., Popov, A., & Kerner, T. (2026). Comparison of Two Analgosedation Regimens in Transfemoral TAVI: Propofol-Dexmedetomidine vs. Propofol-Remifentanil. The Heart Surgery Forum, 29(4). https://doi.org/10.31083/hsf47124
Vancouver
Merks ET, Heide MVD, Meyer-Jark T, Wille C, Popov A, Kerner T. Comparison of Two Analgosedation Regimens in Transfemoral TAVI: Propofol-Dexmedetomidine vs. Propofol-Remifentanil. The Heart Surgery Forum. 2026;29(4). doi:10.31083/hsf47124
BibTeX
@article{Merks2026,
author = {Merks, Erik Thies and Heide, Michael von der and Meyer-Jark, Ties and Wille, Carolin and Popov, Aron-Frederik and Kerner, Thoralf},
title = {Comparison of Two Analgosedation Regimens in Transfemoral TAVI: Propofol-Dexmedetomidine vs. Propofol-Remifentanil},
journal = {The Heart Surgery Forum},
year = {2026},
volume = {29},
number = {4},
doi = {10.31083/hsf47124}
}
EUVIMED